Hansa Biopharma Ab Stock Earnings Reports

Hansa Biopharma reported Q1 2026 revenue of SEK 34.6m (−48% y/y), driven by SEK 33.9m product sales and continuing quarter-to-quarter volatility tied to organ allocation dynamics in Europe. Management characterized Q1 as a transition quarter during which they completed a major commercial reorganization in Europe, strengthened the U.S. leadership team and advanced regulatory activities. Key financial actions in Q1 included raising a USD 30m convertible note, paying down ~SEK 15m of NovaQuest debt, and ending the quarter with cash and cash equivalents of SEK 677m, giving the company an extended runway into/through key clinical and regulatory milestones. Clinical and regulatory highlights: the PAES (European post‑authorization) database lock is expected next month; ConfIdeS (U.S. Phase III) detailed data will be presented at ATC in June; the BLA review in the U.S. is progressing with no unexpected issues reported and a PDUFA date expected in December; and the next‑generation IgG‑cleaving enzyme (HNSA‑5487) showed favorable healthy‑volunteer data and a GBS development plan has been submitted to FDA (response expected in May). Operationally, management expects the recent European commercial changes, new systems (e.g., CRM/dashboards) and targeted market access work (e.g., Catalonia reimbursement, German consensus guidance) to drive recovery and growth through 2026, with full U.S. commercial build planned in Q4 ahead of potential approval. Q1 operating loss widened versus prior quarter; SG&A increased vs prior year (investments in launch prep, LTIP and financing fees) while R&D trended lower as trials wind down.